oncosynergy

OncoSynergy submits FDA application for clinical trial of therapy for malignant brain cancer

OncoSynergy submits FDA application for clinical trial of therapy for malignant brain cancer

Glioblastoma is the most common primary brain cancer in adults.

Infuseon, OncoSynergy Partner on Direct Delivery of mAb Therapy for Glioblastoma

Infuseon, OncoSynergy Partner on Direct Delivery of mAb Therapy for Glioblastoma

The firms’ strategic alliance aims to establish proof of concept that OS2966 can be delivered directly to the brain